These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24397896)

  • 1. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
    Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
    Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
    Asensio CJ; Gaillard ME; Moreno G; Bottero D; Zurita E; Rumbo M; van der Ley P; van der Ark A; Hozbor D
    Vaccine; 2011 Feb; 29(8):1649-56. PubMed ID: 21211579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
    Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
    Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against
    Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D
    Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the immune response induced by pertussis OMVs-based vaccine.
    Bottero D; Gaillard ME; Zurita E; Moreno G; Martinez DS; Bartel E; Bravo S; Carriquiriborde F; Errea A; Castuma C; Rumbo M; Hozbor D
    Vaccine; 2016 Jun; 34(28):3303-9. PubMed ID: 27151884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
    Kang KR; Huh DH; Kim JA; Kang JH
    BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
    Lavigne MV; Castro M; Andino J; Manghi M
    Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
    Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles.
    Ormazábal M; Bartel E; Gaillard ME; Bottero D; Errea A; Zurita ME; Moreno G; Rumbo M; Castuma C; Flores D; Martín MJ; Hozbor D
    Vaccine; 2014 Oct; 32(46):6084-90. PubMed ID: 25240753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
    Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
    Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen.
    Lavigne MV; Castro M; Mateo N; Deluchi S; Atzori C; Piudo L; Calcagno M; Brero ML; Manghi M
    Microbes Infect; 2002 Jul; 4(8):815-20. PubMed ID: 12270728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
    Koepke R; Eickhoff JC; Ayele RA; Petit AB; Schauer SL; Hopfensperger DJ; Conway JH; Davis JP
    J Infect Dis; 2014 Sep; 210(6):942-53. PubMed ID: 24903664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.